The Top Vaccine Stocks that Could Still Run Higher

With COVID-19 cases rocketing across the U.S., we need a vaccine immediately.

Fortunately, we may be close to one.

Just yesterday, Moderna (MRNA) announced its vaccine was found to induce immune responses in every volunteer in a Phase 1 study.

“These early results, published in the New England Journal of Medicine on Tuesday, showed that the vaccine worked to trigger an immune response with mild side effects — fatigue, chills, headache, muscle pain, pain at the injection site — becoming the first US vaccine candidate to publish results in a peer-reviewed medical journal,” says CNN.

Plus, according to Investor’s Business Daily, “A midsize dose of the coronavirus vaccine generated several times more antibodies following a second injection than the level seen in patients who’ve already recovered from Covid-19. The presence of antibodies could indicate a person is immune to the virus.”

Now, the company is preparing to move into Phase 3 studies.   If it sees further success, MRNA could easily run to $100 a share, 

BioNTech (BNTX) and Pfizer (PFE)

The U.S. FDA “fast tracked” a vaccine in development with Pfizer and BioNTech.  

According to BioNTech, two of the company’s four investigational candidates from its BNT162 mRNA-based program being developed to help protect against the virus were “fast tracked.”  

Going forward, Pfizer and BioNTech expect to start the next phase of the vaccine trial later this month with 30,000 subjects.  If successful, the two expect to have 100 million doses of the vaccine by the close of 2020, and more than 1.2 billion by the end of 2021.

AstraZeneca (AZN)

Shares of AstraZeneca are up on news a medical journal will release positive news on the coronavirus vaccine the company is developing with University of Oxford researchers, according to Bloomberg.  “Results from early tests of the vaccine in people will be published by The Lancet, perhaps Thursday.”